What is the starting dose of tesamorelin?

Tesamorelin starts at full dose from day one — no ramp-up.

What is tesamorelin's half-life?

Tesamorelin's half-life is about 26 to 38 minutes.

Is tesamorelin FDA-approved?

Yes, tesamorelin was FDA-approved in November 2010 for reduction of excess abdominal fat in HIV-infected adults.

What are the most common side effects of tesamorelin?

The most common side effects are injection-site reactions, fluid retention, joint pain, and muscle aches.

How do you reconstitute tesamorelin?

Add bacteriostatic water slowly down the inside wall of the vial.

How much bacteriostatic water should be added to tesamorelin?

Common setups are 0.5 to 1.0 mL for a 2 mg vial, 1.0 to 2.5 mL for a 5 mg vial, and 2.0 to 5.0 mL for a 10 mg vial.

What results can be expected from tesamorelin?

Phase III trials showed visceral fat reduction of about 12-20% over 26 weeks.

How does tesamorelin compare to sermorelin and CJC-1295?

Tesamorelin is the only one with current FDA approval and Phase III trial data showing visceral fat reduction.

Metabolic supportsubcutaneous

Tesamorelin

Tesamorelin is a stabilized analog of GHRH studied in lipid-distribution and growth-hormone-axis research.

Researched for

Metabolic HealthBody CompositionCognitive Support

Not yet audited

We have not published an audit on Tesamorelin. Everything below is reference material, not our own reading of the literature, treat it as a starting point for questions, not as a grade.

How it is thought to work

GHRH receptor agonist; GH axis modulation.

Tesamorelin tells your pituitary gland to release more of your own growth hormone in its natural pulsing rhythm, which then drives the body to break down deep belly fat and liver fat more than other fat stores.

Reported side effects

The most common side effects are injection-site reactions like redness, itching, and swelling, along with possible fluid retention, joint pain, muscle aches, elevated blood sugar, and antibody development in about half of long-term users.

Who should avoid it

People with active cancer, pregnancy, a known allergy to tesamorelin or mannitol, or major hypothalamus or pituitary problems should not use tesamorelin, and those with diabetes, a cancer history, or diabetic eye disease should use it only with careful clinician oversight.

What gets monitored

Check blood sugar before starting and at intervals during use. [Source: Peptide Dosing Protocols]

What sources report

Reference, not a recommendation

These are figures published elsewhere, reproduced with their source. Peppersite does not recommend an amount for Tesamorelin or for anything else, and nothing below has been checked against the study it came from.

Amount	Frequency	Route	Reported by
1-2 mg SC daily at bedtime	once daily at bedtime12+ weeks · Continuous per provider direction	subcutaneous	Commonly published practitioner dosing range - provider confirmation required.
2 mg	Once daily	subcutaneous	Peptide Protocol Wiki What it saysHide (secondary reference; provider confirmation required).
Standard: 2 mg once a day	Once daily26 weeks · Cycle length Planning note 4 weeks 6 vials (10 mg) 28 daily doses needed.	Subcutaneous injection in the abdomen only	Peptide Dosing Protocols What it saysHide (secondary reference; provider confirmation required). Half-life: Half-Life Tesamorelin 26-38 minutes Sermorelin 11-12 minutes CJC-1295(DAC) ~6-8 days Fe. The standard dosing for Tesamorelin is 2 mg administered once daily.
Fat loss stacking reference: 200 mcg (0.2 mg) fasted morning paired with AOD-9604 300 mcg. Cited for visceral fat targeting with Mod GRF 1-29 as a pulse-enhancing partner.	Daily in stack contexts · Morning, fasted	subcutaneous	Peptide Therapy Reference Text, internal KB v4 What it saysHide (Aug 2026), secondary reference; provider confirmation required.

1-2 mg SC daily at bedtime

Frequency: once daily at bedtime12+ weeks · Continuous per provider direction
Route: subcutaneous
Reported by: Commonly published practitioner dosing range - provider confirmation required.

2 mg

Frequency: Once daily
Route: subcutaneous
Reported by: Peptide Protocol Wiki
What it saysHide
(secondary reference; provider confirmation required).

Standard: 2 mg once a day

Frequency: Once daily26 weeks · Cycle length Planning note 4 weeks 6 vials (10 mg) 28 daily doses needed.
Route: Subcutaneous injection in the abdomen only
Reported by: Peptide Dosing Protocols

Reconstitution, as reported

Commonly 2 mg vials · Reconstitute with sterile/bacteriostatic water
Reconstitute with bacteriostatic water